Model for Heart Failure ExAcerbation Reduction Trial
| Status: | Completed |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/12/2017 |
| Start Date: | November 2012 |
| End Date: | October 2014 |
Model for Heart Failure ExAcerbation Reduction Trial - "Model HEART"
Heart failure is the leading cause of hospitalizations and readmissions in the United States
and is a tremendous economic strain on our healthcare system. There is currently, based on
national averages, a 30% readmission rate and 10% mortality rate within 3 months of being
hospitalized for heart failure. Retrospective studies have shown benefit to using biomarkers
such as BNP to guide inpatient heart failure management. Our own CCF retrospective study
showed that decreasing NT-ProBNP by 23%, making patients fluid negative by more than 1.3L,
and discharging patients with serum sodium above 135 reduces readmission rates
significantly. The purpose of this study is to prospectively use the above mentioned goals
in the treatment of heart failure in order to reduce heart failure readmission and mortality
rates.
and is a tremendous economic strain on our healthcare system. There is currently, based on
national averages, a 30% readmission rate and 10% mortality rate within 3 months of being
hospitalized for heart failure. Retrospective studies have shown benefit to using biomarkers
such as BNP to guide inpatient heart failure management. Our own CCF retrospective study
showed that decreasing NT-ProBNP by 23%, making patients fluid negative by more than 1.3L,
and discharging patients with serum sodium above 135 reduces readmission rates
significantly. The purpose of this study is to prospectively use the above mentioned goals
in the treatment of heart failure in order to reduce heart failure readmission and mortality
rates.
All HF patients admitted to CCF will receive a short consent form. The study will enroll
patients for one year. Physicians will initiate / titrate medications and obtain consults as
usual but are highly encourage to keep patients in the hospital until at least 2 of the 3
(above mentioned) criteria are met. Physicians will receive a copy of consent forms,
educational bulletins, and discharge forms (as described in the Physician Education document
which is attached to this application). Log-rank test will be used to compare groups.
Chi-Square will be used to compare prospective patients with retrospective controls
(obtained in 2010).
patients for one year. Physicians will initiate / titrate medications and obtain consults as
usual but are highly encourage to keep patients in the hospital until at least 2 of the 3
(above mentioned) criteria are met. Physicians will receive a copy of consent forms,
educational bulletins, and discharge forms (as described in the Physician Education document
which is attached to this application). Log-rank test will be used to compare groups.
Chi-Square will be used to compare prospective patients with retrospective controls
(obtained in 2010).
Inclusion Criteria:
- Must have either Acute on Chronic Heart Failure or Chronic Heart Failure regardless
of presenting/primary complaint
To fulfill CHF Dx, MUST have 2+ of the following:
- Clinical: Dyspnea, orthopnea, PND, edema, S3, rales, improve w diuretics
- Radiographic: Pulm venous congestion, pleural effs, cardiomegaly
- Lab: NT pro BNP > 1000
Exclusion Criteria:
We found this trial at
1
site
Cleveland Clinic Florida Cleveland Clinic Florida, located in Weston, West Palm Beach, Palm Beach Gardens...
Click here to add this to my saved trials
